Addex Therapeutics Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Addex Therapeutics Ltd
Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
Rather than expose patients and others to SARS-CoV-2, Provention opted to pause a Phase III type 1 diabetes trial. Addex and Iveric have since delayed trial initiations and more studies are likely to be impacted as coronavirus concerns mount.
The barriers for health-care industry entrants into China are lowering, but still not as quickly as many medtech companies would like. New structural health-care delivery plans are instilling more confidence in a market and industry that in the past have been regarded with caution.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Addex Pharmaceuticals